Clinical Trial

NICU Antibiotics and Outcomes (NANO) Follow-up Study

Study acronym: NANO-FU
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The NANO follow-up study is designed to determine whether a simple, cost-effective intervention- withholding antibiotics at birth- reduces clinically relevant outcomes such as behavioral and neurological impairment at 2 years of age. This study will be the largest study evaluating the effects of early antibiotics in children with comprehensive measures of neurodevelopment linked to genomic variants and microbiota interactions.
Trial Details
NCT Number NCT05977400
Lead Sponsor Sharp HealthCare
Collaborators: University of Pittsburgh, Morgan Stanley Children's Hospital, University of Louisville, Sharp Mary Birch Hospital for Women & Newborns, Children's Hospital of Philadelphia, Jefferson Medical College of Thomas Jefferson University, University of South Florida, Westchester Medical Center, Yale University, The University of Texas Health Science Center at San Antonio, Penn State University, State University of New York - Downstate Medical Center, Mount Sinai Hospital, Canada
Conditions Premature Birth, Antibiotics, Neurodevelopment
Enrollment 802 participants
Start Date 2024-04
Primary Completion 2029-03 (estimated)
Study Completion 2029-03 (estimated)
Updated on ClinicalTrials.gov 2023-08-04